[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "Emeryville", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 62, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 60, "title": "Co-Founder, CEO & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1008093, "exercisedValue": 0, "unexercisedValue": 308925}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 60, "title": "President & COO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 786201, "exercisedValue": 0, "unexercisedValue": 3869287}, {"maxAge": 1, "name": "Dr. Noriyuki  Kasahara M.D., Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 201288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. An  Song Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.", "age": 62, "title": "Senior VP & Therapeutic Area Head of Pulmonology", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen S. Carothers", "age": 72, "title": "Controller", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 26.75, "open": 26.94, "dayLow": 25.145, "dayHigh": 26.99, "regularMarketPreviousClose": 26.75, "regularMarketOpen": 26.94, "regularMarketDayLow": 25.145, "regularMarketDayHigh": 26.99, "beta": 2.862, "forwardPE": -7.441176, "volume": 500700, "regularMarketVolume": 500700, "averageVolume": 1233264, "averageVolume10days": 528710, "averageDailyVolume10Day": 528710, "bid": 25.28, "ask": 25.35, "bidSize": 100, "askSize": 100, "marketCap": 1294284672, "fiftyTwoWeekLow": 9.44, "fiftyTwoWeekHigh": 36.25, "priceToSalesTrailing12Months": 62.456432, "fiftyDayAverage": 29.0552, "twoHundredDayAverage": 18.980675, "currency": "USD", "enterpriseValue": 985825600, "floatShares": 31641466, "sharesOutstanding": 51157500, "sharesShort": 9317980, "sharesShortPriorMonth": 8344171, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.1872, "heldPercentInsiders": 0.03534, "heldPercentInstitutions": 0.85524005, "shortRatio": 12.24, "shortPercentOfFloat": 0.234, "impliedSharesOutstanding": 51157500, "bookValue": 7.146, "priceToBook": 3.5404422, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -100837000, "trailingEps": -2.58, "forwardEps": -3.4, "pegRatio": 0.54, "enterpriseToRevenue": 47.572, "enterpriseToEbitda": -9.072, "52WeekChange": 0.27327633, "SandP52WeekChange": 0.2160933, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FDMT", "underlyingSymbol": "FDMT", "shortName": "4D Molecular Therapeutics, Inc.", "longName": "4D Molecular Therapeutics, Inc.", "firstTradeDateEpochUtc": 1607697000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3c71667a-4f1e-3d28-8cb0-26ab7aa9e925", "messageBoardId": "finmb_272879653", "gmtOffSetMilliseconds": -14400000, "currentPrice": 25.3, "targetHighPrice": 82.0, "targetLowPrice": 34.0, "targetMeanPrice": 52.2, "targetMedianPrice": 45.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 288232000, "totalCashPerShare": 5.79, "ebitda": -108663000, "totalDebt": 14671000, "quickRatio": 15.209, "currentRatio": 15.65, "totalRevenue": 20723000, "debtToEquity": 4.766, "revenuePerShare": 0.53, "returnOnAssets": -0.23446, "returnOnEquity": -0.37405, "freeCashflow": -46483876, "operatingCashflow": -75792000, "grossMargins": 0.52999, "operatingMargins": 1929.0526, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-18"}]